Literature DB >> 8815077

Atmospheric growth requirements for Alloiococcus species and related gram-positive cocci.

P H Miller1, R R Facklam, J M Miller.   

Abstract

The growth of Alloiococcus otitis under different atmospheres and nutritional conditions was studied. The growth rates of 25 strains of gram-positive cocci representing five genera on heart infusion agar plates containing 5% rabbit blood and on brucella agar plates with and without sheep blood under aerobic, increased CO2, and anaerobic atmospheres were compared. Eight strains of alloiococci plated on heart infusion agar with rabbit blood and on brucella sheep blood agar grew under aerobic and candle jar atmospheres. Two of these strains showed poor anaerobic growth after 7 days. Strains of Aerococcus viridans, Aerococcus urinae, Helcococci kunzi, Dolosigranulum pigrum, Gemella haemolysans, and Gemella morbillorum grew well under all three atmospheres and on the three types of media and in thioglycolate broth. These results confirm all the aerobic atmospheric requirements for Alloiococcus strains and show that aerobic growth characteristics help distinguish the alloiococci from the other gram-positive cocci that are facultatively anaerobic.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8815077      PMCID: PMC228947          DOI: 10.1128/jcm.34.4.1027-1028.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  3 in total

1.  Recovery of a unique bacterial organism in human middle ear fluid and its possible role in chronic otitis media.

Authors:  H Faden; D Dryja
Journal:  J Clin Microbiol       Date:  1989-11       Impact factor: 5.948

Review 2.  Identification, classification, and clinical relevance of catalase-negative, gram-positive cocci, excluding the streptococci and enterococci.

Authors:  R Facklam; J A Elliott
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

3.  Phylogenetic analysis of Alloiococcus otitis gen. nov., sp. nov., an organism from human middle ear fluid.

Authors:  M Aguirre; M D Collins
Journal:  Int J Syst Bacteriol       Date:  1992-01
  3 in total
  8 in total

1.  Antimicrobial susceptibility and clinical sources of Dolosigranulum pigrum cultures.

Authors:  L Laclaire; R Facklam
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

2.  Antimicrobial susceptibilities and clinical sources of Facklamia species.

Authors:  L LaClaire; R Facklam
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

3.  Comparison of three commercial rapid identification systems for the unusual gram-positive cocci Dolosigranulum pigrum, Ignavigranum ruoffiae, and Facklamia species.

Authors:  L L LaClaire; R R Facklam
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

4.  Acute cholecystitis accompanied by acute pancreatitis potentially caused by Dolosigranulum pigrum.

Authors:  Jung-Chung Lin; Shu-Jin Hou; Li-Ung Huang; Jun-Ren Sun; Wei-Kuo Chang; Jang-Jih Lu
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

5.  Ventilator-associated pneumonia caused by Dolosigranulum pigrum.

Authors:  A Hoedemaekers; T Schülin; B Tonk; W J G Melchers; P D J Sturm
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

6.  Case of synovitis potentially caused by Dolosigranulum pigrum.

Authors:  G S Hall; S Gordon; S Schroeder; K Smith; K Anthony; G W Procop
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

7.  Use of multiplex PCR for simultaneous detection of four bacterial species in middle ear effusions.

Authors:  P H Hendolin; A Markkanen; J Ylikoski; J J Wahlfors
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

8.  Dolosigranulum pigrum keratitis: a three-case series.

Authors:  Magali Sampo; Oaufeh Ghazouani; Dominique Cadiou; Elodie Trichet; Louis Hoffart; Michel Drancourt
Journal:  BMC Ophthalmol       Date:  2013-07-10       Impact factor: 2.209

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.